Compare VIR & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIR | SLRC |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 773.5M | 771.9M |
| IPO Year | 2019 | 2010 |
| Metric | VIR | SLRC |
|---|---|---|
| Price | $6.78 | $15.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 7 |
| Target Price | ★ $25.73 | $16.04 |
| AVG Volume (30 Days) | ★ 1.8M | 264.5K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 10.47% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.65 |
| Revenue | $16,860,000.00 | ★ $219,666,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.05 | N/A |
| P/E Ratio | ★ N/A | $9.48 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $13.64 |
| 52 Week High | $14.45 | $17.94 |
| Indicator | VIR | SLRC |
|---|---|---|
| Relative Strength Index (RSI) | 61.51 | 49.50 |
| Support Level | $6.49 | $15.97 |
| Resistance Level | $6.89 | $16.14 |
| Average True Range (ATR) | 0.47 | 0.19 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 83.17 | 36.52 |
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.